TTP 4000
Alternative Names: TTP4000Latest Information Update: 12 Apr 2016
At a glance
- Originator TransTech Pharma
- Developer vTv Therapeutics LLC
- Class
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 01 Oct 2011 Phase-I clinical trials in Alzheimer's disease (In adults, In the elderly) in USA (SC) (NCT01548430)
- 12 Aug 2009 Preclinical development is ongoing in USA
- 21 Sep 2006 TransTech Pharma and Pfizer have entered into an license agreement for the development and commercialisation of RAGE modulators worldwide